Background
Phase 3 open-label RCT (COMMODORE 2). Complement inhibitor-naïve adult PNH patients with LDH ≥1.5× ULN and ≥1 PNH symptom, randomized 2:1. Crovalimab (RG6107/SKY59; Piasky) is a novel recycling anti-C5 monoclonal antibody engineered with pH-dependent antigen binding, enabling FcRn-mediated recycling for extended half-life and predominantly subcutaneous dosing at 4-week intervals after an initial loading period (IV+SC). FDA approved June 2024.
Interventions and follow up
Arm A: Crovalimab — loading (IV 1000 mg day 1; SC 340 mg days 2, 8, 15, 22), then SC 340 mg every 4 weeks
Arm B: Eculizumab 600 mg IV weekly × 4, then 900 mg IV every 2 weeks
Primary endpoint: LDH normalization at week 25 (non-inferiority margin 12%)
Median follow up: 24 weeks
Arm B: Eculizumab 600 mg IV weekly × 4, then 900 mg IV every 2 weeks
Primary endpoint: LDH normalization at week 25 (non-inferiority margin 12%)
Median follow up: 24 weeks
Results
LDH normalization: 79.3% (crovalimab) vs 79.0% (eculizumab); difference −0.3% (95% CI −10.7, 10.1) — non-inferior (lower bound >−12%)
Transfusion avoidance: 65.7% vs 68.1%
Breakthrough hemolysis: 5.0% vs 5.4%
FACIT-Fatigue improvement: +7.7 vs +8.5 points
Transfusion avoidance: 65.7% vs 68.1%
Breakthrough hemolysis: 5.0% vs 5.4%
FACIT-Fatigue improvement: +7.7 vs +8.5 points
Adverse events
Grade ≥3 AEs: similar between arms; serious AEs similar; no treatment-related deaths
Injection site reactions (crovalimab SC): mild-moderate in ~15%, grade ≥3 rare
Infections: no meningococcal infections (all vaccinated); headache common to both arms
Injection site reactions (crovalimab SC): mild-moderate in ~15%, grade ≥3 rare
Infections: no meningococcal infections (all vaccinated); headache common to both arms
Conclusions
Crovalimab given primarily subcutaneously every 4 weeks was non-inferior to intravenous eculizumab every 2 weeks for LDH normalization in complement-naïve PNH, with a similar safety profile, offering a more convenient dosing option.
Key Limitations
Design: open-label; non-inferiority trial — superiority not claimed
Duration: 24-week primary analysis period is short
Mechanism: as a C5 inhibitor crovalimab does not address extravascular hemolysis; SC administration requires patient training and appropriate injection technique
Duration: 24-week primary analysis period is short
Mechanism: as a C5 inhibitor crovalimab does not address extravascular hemolysis; SC administration requires patient training and appropriate injection technique
Clinical Context
FDA approved June 2024 (Piasky) for PNH. Crovalimab offers a more convenient SC q4w option vs IV eculizumab q2w or IV ravulizumab q8w; in the C5-inhibition landscape crovalimab, ravulizumab, and eculizumab are comparably efficacious, with choice driven by patient preference. Iptacopan (oral factor B inhibitor, FDA approved Oct 2023) and pegcetacoplan (SC C3 inhibitor) address extravascular hemolysis for patients with persistent anemia on C5 inhibitors.